New CEO gets rid of a number of Ambu executives Medtech firm Ambu has had major changes in Europe, after Juan Jose Gonzalez took over as CEO when Lars Marcher was fired. Ambu CEO Juan Jose Gonzalez. | Photo: Ambu/PR BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY NIELSINE NIELSEN Published: 07.12.20 at 21:07 The old veterans need to find something else to spend their time on. This seems to be the signal sent when Ambu CEO Juan Jose Gonzalez got rid of several of the firm's most loyal employees in the hastily growing medtech firm. Already a subscriber? Log in. Read the whole article Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial. Access all locked articles Receive our daily newsletters Access our app First name: Last name: E-mail address: Password: I accept the terms and conditions An error has occured. Please try again later. Create trial Get full access for you and your coworkers. Start a free company trial today More from MedWatch Long wait for IVDR implementation is over, putting an end to pandemic "wild west" After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26. GN purchase story is very speculative, says analyst Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway. US to start using Bavarian vaccine stockpile In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease. Bavarian Nordic upgrades guidance following vaccine contract Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year. Novo Nordisk invests additional millions of dollars in new manufacturing facilities Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location. Print Print Increase text size Increase text size Decrease text size Decrease text size Further reading GN purchase story is very speculative, says analyst GN Hearing in talks with VA on new hybrid product category GN Hearing lets staff go to optimize supply chain CHMP to remove 100 generic medicines from market Novo Nordisk invests additional millions of dollars in new manufacturing facilities Related articles Coloplast CEO: I can calmly declare that the best times are ahead of us Former Widex CEO on chairman prospects: I can deliver in every area Ambu ready for price war on market for single-use devices Coloplast CEO on expectations: "There are many swing factors" Lars Rasmussen sees no conflict in double chairmanship: "Although there's nothing to it, bad publicity could harm Ambu"